Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Reclassification of giraffe status pivotal in public action, says UFS researcher
2016-12-08

Description: Reclassification of giraffe status  Tags: Reclassification of giraffe status  

Dr Francois Deacon, specialised researcher
in the Department of Animal, Wildlife, and
Grassland Sciences at the University of the Free State.
Photo: Supplied

Great news for those who care about the conservation of giraffes is today’s (8 December 2016) announcement by the International Union for the Conservation of Nature (IUCN) that giraffes are now classified as ‘Vulnerable’. The species, formerly classified as ‘Least Concern’ on the IUCN Red List — an index on the likelihood of extinction of animals worldwide — is threatened with extinction.

“Until recently, few people were aware of the situation facing giraffes. It is time to show the world giraffe numbers are in danger. This reclassification by the IUCN is pivotal to get the public to stand up and take action for giraffes,” said Dr Francois Deacon, specialised researcher in the Department of Animal, Wildlife, and Grassland Sciences at the University of the Free State (UFS).

Research is essential to develop effective conservation plans for a species

Key to this announcement was the status report submitted by Dr Deacon. He was the lead author responsible for the submission of the Southern African Giraffe subspecies (Giraffa camelopardalis giraffa) status report that was part of the larger species report submitted for review by the (IUCN). The UFS has been doing many research projects in the past couple of years on giraffe-related issues and topics to address this problem.

The UFS is one of only a few universities in Africa that is committed to studying giraffes to ensure the conservation of this species for generations to come.

“The reclassification of giraffes to ‘Vulnerable’
status, by the IUCN, is pivotal to get the public
to stand up and take action for giraffes.”

A 40% decline in the giraffe population over the past two decades is proof that the longnecks are officially in trouble. According to Dr Deacon, this rate of decline is faster than that of the elephant or rhino. The main reasons for the devastating decline are habitat loss, civil unrest and illegal hunting.

Dr Deacon, pioneer in the use of GPS technology to study giraffes and their natural habitat, said “This vulnerability clearly stipulates we are quickly losing grip on our last few natural populations”. He and a team of researchers at the UFS in South Africa are leading various research and conservation projects to help save the last remaining giraffes in Africa.

Giraffes moved from ‘least concern’ to ‘vulnerable’ on the Red List

The IUCN, a health check for our planet, is the highest level at which decision-makers can prove how many species (fauna or flora) are surviving or not. The update from ‘Least Concern’ to ‘Vulnerable’ on the Red List was released at the 13th Conference of the Parties to the Convention on Biological Diversity in Cancun, Mexico.

A wildlife documentary, Last of the Longnecks clearly shows how the number of giraffes has plummeted in the past two decades from 154 000 to fewer than 98 000 today — with numbers of some giraffes, such as Kenya’s reticulated giraffe, declining by as much as 80%.  

Any individual or institution that wants to make a contribution relating to giraffe research can contact Dr Deacon at the UFS on deaconf@ufs.ac.za.

 

In other media:

Announcement on BBC news: http://www.bbc.co.uk/news/science-environment-38240760
Time: http://time.com/3622344/giraffe-extinction/
The Telegraph: http://www.telegraph.co.uk/science/2016/12/08/giraffes-now-facing-extinction-warn-conservationists/
ABC News: http://abcnews.go.com/International/giraffes-danger-extinction-numbers-dropped/story?id=27334959
theguardian: https://www.theguardian.com/environment/2016/dec/08/giraffe-red-list-vulnerable-species-extinction
Aol: http://www.aol.co.uk/news/2016/12/07/giraffes-in-danger-of-extinction-as-population-plunges-by-up-to/  

 

Former articles:

18 November 2016: Studies to reveal correlation between terrain, energy use, and giraffe locomotion
23 August 2016:
Research on locomotion of giraffes valuable for conservation of this species
9 March 2016:
Giraffe research broadcast on National Geographic channel
18 September 2015:
Researchers reach out across continents in giraffe research
29 May 2015:
Researchers international leaders in satellite tracking in the wildlife environment

 



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept